BARABE TIMOTHY C 4

4 · Cartesian Therapeutics, Inc. · Filed Nov 15, 2023

Form 4

Period: 2023-11-13

Director

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2023-11-13−10,328→ 0 total
Exercise: $11.00Exp: 2026-07-28→ Common Stock (10,328 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-13−6,410→ 0 total
Exercise: $17.47Exp: 2027-06-15→ Common Stock (6,410 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-13−10,000→ 0 total
Exercise: $12.75Exp: 2028-06-14→ Common Stock (10,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-13−20,000→ 0 total
Exercise: $3.00Exp: 2030-06-18→ Common Stock (20,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-13−40,000→ 0 total
Exercise: $4.01Exp: 2031-03-29→ Common Stock (40,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-13−40,000→ 0 total
Exercise: $3.31Exp: 2032-01-02→ Common Stock (40,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-13$0.93/sh−87,500$81,375→ 0 total
Exercise: $1.13Exp: 2033-01-01→ Common Stock (87,500 underlying)

Footnotes (7)

[F1]This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on July 29, 2016, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
[F2]This option, which provided for vesting in full on June 14, 2018, was canceled in the Merger.
[F3]This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger.
[F4]This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
[F5]This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
[F6]This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
[F7]This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.

Documents

1 file